Transforming Gastrointestinal Health

Geneoscopy is passionate about the work we do, committed to excellence and believes that improvements in personalized medicine can impact the lives of patients with gastrointestinal diseases.

Learn more

Our Mission

To empower patients and healthcare providers to transform gastrointestinal health with our innovative tests that help prevent, detect, and monitor disease.

Enabled by molecular technologies that have led to new disease biology insights, precision medicine has become the standard of care in some areas of medicine, especially oncology. As a result, there is a great need to bring this approach to gastrointestinal disease management. A new generation of noninvasive, molecular-based colorectal cancer screening tests is being developed to enable the prevention and early detection of colorectal cancer. Meanwhile, the clinical community is beginning to embrace the value of diagnostics in diagnosing and managing GI diseases, such as ulcerative colitis and Crohn’s disease. With its innovative stool-derived eukaryotic RNA (seRNA) technology platform, Geneoscopy is at the forefront of these exciting frontiers to make the screening for colorectal cancer and other GI diseases safe, effective, convenient, and accessible.

Our Story

Explore

Our Science

Explore

Our Progress

Explore

Our Future

Explore

Our Continued commitment to early cancer detection

Since the beginning, our founders have been committed to bridging the gap in colorectal cancer screening rates.

Due primarily to the inconvenience and invasive nature of colonoscopies, over 40% of eligible patients fail to get screened. Despite being very preventable, colorectal cancer (CRC) is the second deadliest cancer in the US, causing over 50,000 deaths each year.¹

Geneoscopy’s noninvasive stool-based solution can reduce the barriers to screening and help address the gap in health equity.